There are currently 5 FDA-approved stimulants for the treatment of narcolepsy in patients ages 6 and older, while there is only one psychotropic, duloxetine, which is FDA-approved for generalized anxiety disorder in child and adolescent populations. Due to lack of clinical trials in pediatric psychiatric medicine, the PMHNP frequently prescribes off-label based on existing data on adult treatment response, adjusting doses according to weight and variability in metabolic profile. As a future psychiatric nurse practitioner, do you anticipate FDA-approval influencing your prescribing strategies for this specialized population? Why or why not. Give at least two rationales for your response, then respond to two other classmates.